ImmixBio announces FDA Orphan drug designation for IMX-110 for the treatment of Soft Tissue Sarcoma

Latest pharma news update

Immix Biopharma, Inc., a biotechnology company pioneering Tissue-Specific Therapeutics (TSTx)TM for oncology and inflammation, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to IMX-110 for the treatment of soft tissue sarcoma.

The FDA’s Office of Orphan Products Development grants orphan designation status to drugs and biologics that are intended for the safe and effective treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. Orphan Drug Designation provides certain benefits, including financial incentives, to support clinical development and the potential for up to 7 years of market exclusivity in the U.S. upon regulatory approval.

“We are pleased to receive FDA’s orphan drug designation in soft tissue sarcoma for IMX-110, the first clinical-stage product of our SMARxT Tissue-Specific Platform,” said Ilya Rachman MD PhD, ImmixBio Founder & CEO. “We are thrilled to potentially contribute to expanding therapeutic options for oncology patients, beginning with soft tissue sarcoma.”

Gabriel Morris, ImmixBio Chief Financial Officer, added: “Orphan drug designation for IMX-110 represents a substantial value creating step along our path of building a strong, independent biopharmaceutical organization.”

Tags : #Immixbio #SoftTissueSarcoma #IMX110 #FDANews #FDAApprovalsLatest

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Preparing for the Future: FDA's New COVID-19 Vaccine Recommendation Focuses on KP.2June 17, 2024
From Pap Tests to HPV Screening: A New Era in Cervical Cancer PreventionJune 17, 2024
Rare H9N2 Bird Flu Case Found in Four-Year-Old in India: WHO Highlights Ongoing RisksJune 15, 2024
Kerala Government Announces Aid Package After Kuwait Fire TragedyJune 15, 2024
EV Conference 24---Charging Up for e-mobility Minister Ponnam Prabhakar and Jayesh Ranjan among others to graceJune 14, 2024
Are we on track to end AIDS, end viral hepatitis and end STIs by 2030?June 14, 2024
HR Conclave Focusing on Future-Forward Engineering where Engineering and Management students meet their future employees, thus exposing students to real-world HR challenges and innovative solutionsJune 14, 2024
MAGGI Empowers 10 Women to Bring their Entrepreneurial dreams to lifeJune 13, 2024
FTCCI announced its Annual Excellence Awards and invites entries, last date is 20th June 2024June 13, 2024
Bird Flu Cases by Dr Praveen Gupta, Principle Director and Chief of Neurology, Fortis Hospital.June 13, 2024
Sova Health's $1 Million Seed Funding to Drive Gut Health InnovationJune 13, 2024
The Vital Role of Early Detection: Kevin Jonas on Battling Skin CancerJune 13, 2024
Zumutor Biologics Advances Cancer Care with Novel Immunotherapy ZM008: A First-in-Class Anti LLT1 AntibodyJune 13, 2024
HP Ghosh Hospital Unveils Innovative "Chest Tree" June 12, 2024
Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, IndiaJune 12, 2024
From the frontlines: Homeless person won over alcoholism, survived floods and defeated TBJune 12, 2024
The Role of Hormones in Obesity: Why Men and Women Gain Weight DifferentlyJune 12, 2024
Silent Killer: How a Young Mother’s Vision Loss Led to a Lung Cancer DiagnosisJune 12, 2024
TruAlt Bioenergy’s subsidiary, Leafiniti Bioenergy supplies over 1000 tons of Compressed Biogas to AG&P Pratham in just 5 monthsJune 11, 2024
Southeast Asia's Most Advanced Luxury Postpartum Centre Re'Joy Suites Opens in SingaporeJune 11, 2024